5 Key Takeaways

• 1

  The UK MHRA has authorized aflibercept 8 mg for treating visual impairment due to retinal vein occlusion.

• 2

  This approval is based on the Phase III QUASAR trial, demonstrating non-inferior visual acuity gains compared to aflibercept 2 mg.

• 3

  Patients receiving aflibercept 8 mg required fewer injections on average than those receiving the 2 mg formulation.

• 4

  Over 60% of patients in the 8 mg group achieved treatment intervals of four months or longer by week 64.

• 5

  The authorization aims to reduce injection burden while maintaining visual outcomes for patients with RVO.